 | A major contributor to this article appears to have a close connection with its subject.(October 2025) |
Alec C. Kimmelman is an American physician and researcher who is dean of NYU Grossman School of Medicine and chief executive officer of NYU Langone Health. [1]
Kimmelman earned his bachelor's degree from Cornell University and completed a dual MD/PhD through the Medical Scientist Training Program at the Icahn School of Medicine at Mount Sinai. [2] He joined Harvard Medical School as a clinical fellow, completing his residency in radiation oncology and a postdoctoral fellowship at Dana-Farber. [1] [2]
Kimmelman ran a research program at Dana-Farber Cancer Institute focused on pancreatic cancer. [2] He was also an attending physician at Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he specialized in gastrointestinal malignancies, including pancreatic cancer. [3] [4]
Kimmelman joined NYU Langone in 2016 and has held several leadership roles at the medical center. [5] He served as director of NYU Langone's Laura and Isaac Perlmutter Cancer Center, the Laura and Isaac Perlmutter Professor of Radiation Oncology, the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology, and chair of the Department of Radiation Oncology at NYU Grossman School of Medicine. [6] [5] He was also associate dean of cancer research at the school, served on the Executive Management Committee of the Perlmutter Cancer Center, and co-led its Cancer Cell Biology Program. [5]
In 2025, Kimmelman was appointed dean of NYU Grossman School of Medicine and chief executive officer of NYU Langone Health. [1]
Kimmelman is a National Institutes of Health–funded investigator whose work has primarily focused on pancreatic cancer and the key biological functions of Ras oncogenes. [7] [2] Kimmelman's laboratory was focused on the basic and translational science of pancreatic cancer. [8] His research identified unique metabolic pathways and revealed how the Kras oncogene reprograms tumor metabolism. [8]
Kimmelman's research has been published in Cell, Science, Nature,Cancer Cell,Cancer Discovery and Genes & Development. [9] [10] [11] [12] [13] [14]
In 2023, Kimmelman received a $1.7 million Drug Discovery Award from the Mark Foundation for Cancer Research. [15] Under his leadership, the Perlmutter Cancer Center established the Center for Molecular Oncology in October 2024. [16]